RT Journal Article
SR Electronic
T1 Assessing the causal effect of air pollution on risk of SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.26.23297598
DO 10.1101/2023.10.26.23297598
A1 Navaratnam, Annalan M D
A1 Beale, Sarah
A1 Boukari, Yamina
A1 Nguyen, Vincent
A1 Fong, Wing Lam Erica
A1 Braithwaite, Isobel
A1 Byrne, Thomas E
A1 Fragaszy, Ellen
A1 Geismar, Cyril
A1 Kovar, Jana
A1 Patel, Parth
A1 Shrotri, Madhumita
A1 Yavlinsky, Alexei
A1 Hayward, Andrew C
A1 Khreis, Haneen
A1 Aldridge, Robert W
YR 2023
UL http://medrxiv.org/content/early/2023/10/26/2023.10.26.23297598.abstract
AB Introduction Emerging evidence suggests association of air pollution exposure with risk of SARS-CoV-2 infection, but many of these findings are limited by study design, lack of individual-level covariate data or are specific to certain subpopulations. We aim to evaluate causal effects of air pollution on risk of infection, whilst overcoming these limitations.Methods Concentrations for black carbon(BC), particulate matter 10(PM10), particulate matter 2.5(PM2.5), nitrogen dioxide(NO2) and oxides of nitrogen(NOx) from the Department of Environment, Food and Rural Affairs (DEFRA) and Effect of Low-level Air Pollution: A Study in Europe (ELAPSE) were linked to postcodes of 53,683 Virus Watch study participants. The primary outcome was first SARS-CoV-2 infection, between 1st September 2020 and 30th April 2021. Regression analysis used modified Poisson with robust estimates, clustered by household, adjusting for individual (e.g., age, sex, ethnicity) and environmental covariates(e.g., population density, region) to estimate total and direct effects.Results Single pollutant analysis showed the direct effect of higher risk of SARS-CoV-2 infection with increased exposure to PM2.5(RR1.11,95%CI 1.08;1.15), PM10(RR1.06,95%CI 1.04;1.09), NO2(RR1.04,95%CI 1.04;1.05) and NOx(RR1.02,95%CI 1.02;1.02) per 1µg/m3 increment with DEFRA 2015-19 data. Sensitivity analyses altering covariates, exposure window and modelled air pollution data source produced similar estimates. Higher risk of SARS-CoV-2 per 10-5m-1 increment of BC (RR1.86, 95%CI 1.62;2.14) was observed using ELAPSE data.Conclusion Long term exposure to higher concentrations of air pollutions increases the risk of SARS-CoV-2 infection, highlighting that adverse health effects of air pollution is not only limited to non-communicable diseases.Competing Interest StatementAH serves on the UK New and Emerging Respiratory Virus Threats Advisory Group. AH are members of the COVID-19 transmission sub-group of the Scientific Advisory Group for Emergencies (SAGE).Funding StatementThe research costs for the study have been supported by the MRC Grant Ref: MC_PC 19070 awarded to UCL on 30 March 2020 and MRC Grant Ref: MR/V028375/1 awarded on 17 August 2020. The study also received $15,000 of Facebook advertising credit to support a pilot social media recruitment campaign on 18th August 2020. The study also received funding from the UK Government Department of Health and Social Care's Vaccine Evaluation Programme to provide monthly Thriva antibody tests to adult participants. This study was supported by the Wellcome Trust through a Wellcome Clinical Research Career Development Fellowship to RA [206602]. AMDN was funded through the NIHR Academic Clinical Fellowship (ACF-2021-14-005). HK received funding from the European Research Council (ERC) under the Horizon 2020 research and innovation programme (Grant agreement No. 817754). This material reflects only the author's views, and the Commission is not liable for any use that may be made of the information contained therein.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study involves human participants and Virus Watch was approved by the Hampstead NHS Health Research Authority Ethics Committee (20/HRA/2320) and conformed to the ethical standards set out in the Declaration of Helsinki. Participants gave informed consent to participate in the study before taking part.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesWe aim to share aggregate data from this project on our website and via a “Findings so far” section on our website - https://ucl-virus-watch.net/. We will also be sharing individual record level data on a research data sharing service such as the Office of National Statistics Secure Research Service. In sharing the data we will work within the principles set out in the UKRI Guidance on best practice in the management of research data. Access to use of the data whilst research is being conducted will be managed by the Chief Investigators (ACH and RWA) in accordance with the principles set out in the UKRI guidance on best practice in the management of research data. We will put analysis code on publicly available repositories to enable their reuse.